EGFR and biliary tract neoplasm: At present, a clinical trial (NCT03093870) is ongoing to investigate the safety and efficacy of capecitabine in combination with varlitinib, an inhibitor of EGFR, HER2 and HER4, for the treatment of biliary tract cancer.